10/12/2025
As per the latest review of India’s Medical Device Park Scheme (December 2025), the government is shifting its focus from capacity expansion to deep manufacturing competence. With advanced testing labs, component-level infrastructure, and co-located R&D hubs, India is signalling a decisive move, to own the engineering core of MedTech rather than assemble imported technologies.
For the country’s deeptech ecosystem, this marks a defining inflection. The synergy between the PLI Scheme for Medical Devices and the expanded park framework is creating a rare alignment of infrastructure, funding, and ambition. The next phase of growth will reward those who invest in indigenous sensors, controllers, embedded architectures, and design validation systems that meet the highest global benchmarks.
This evolution will clearly separate engineering leaders from assemblers. As prototyping cycles shorten and compliance standards rise, competitiveness will rest on who can design smarter, validate faster, and scale with consistency. For teams working at the intersection of healthcare, electronics, and embedded systems, this is not just opportunity, it’s a call to lead.
At Morphedo, we see this as India’s defining decade, where localisation converges with innovation and policy meets precision engineering. Our commitment remains clear - to help build a MedTech ecosystem that is not only made in India but engineered to global excellence.
